Affimed N.V. (AFMD)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Wolfgang Fischer Ph.D. | MD, COO, Chief Strategy Officer & Member of Management Board | 603.62k | -- | 1964 |
| Ms. Denise Mueller | Chief Business Officer & Member of Management Board | 540.38k | -- | 1970 |
| Dr. Andreas Harstrick M.D. | Chief Medical Officer & Member of Management Board | 499.32k | -- | 1961 |
| Dr. Shawn M. Leland Pharm.D., R.Ph. | Chief Executive Officer | -- | -- | 1984 |
| Prof. Melvyn Little | Founder & Consultant | -- | -- | -- |
| Mr. Michael Wolf | Head of Finance & Administration | -- | -- | 1967 |
| Mr. Alexander Fudukidis | Head of Investor Relations & Director of Investor Relations | -- | -- | -- |
| Mary Beth Sandin | Vice President of Marketing & Communications | -- | -- | -- |
Affimed N.V.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 76
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
Corporate Governance
Upcoming Events
May 28, 2025 at 12:30 PM UTC - June 12, 2025 at 12:30 PM UTC
Affimed N.V. Earnings Date
Recent Events
May 1, 2025 at 12:00 AM UTC
NT 20-F: Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F
November 8, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission